Inhibition of Bradykinin in COVID-19 Infection With Icatibant

Summary

There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.

Timeline

Start

2022-05-16

Primary completion

2023-06-09

Completion

2023-07-07

Publications

• Bailey M, Linden D, Earley O, Guo Parke H, McAuley DF, Peto T, Taggart C, Kidney J. Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS). BMJ Open. 2023 Nov 30;13(11):e074726. doi: 10.1136/bmjopen-2023-074726.

Drugs

Indications